Mer­ck­'s 21-va­lent pneu­mo­coc­cal vac­cine for adults wins FDA ap­proval

Mer­ck’s 21-va­lent pneu­mo­coc­cal vac­cine was ap­proved by the FDA on Mon­day, bring­ing a new com­peti­tor to mar­ket for Pfiz­er’s 20-va­lent prod­uct.

Mer­ck’s vac­cine, called Cap­vax­ive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.